Zevra Therapeutics, Inc. Payments to Acquire Investments
Zevra Therapeutics, Inc. (ZVRA) reported Payments to Acquire Investments of $129.00 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2024-08-14
- Zevra Therapeutics, Inc. payments to acquire investments for the quarter ending 2023-06-30 was -$59.00K, a 100.30% decline year-over-year.
- Zevra Therapeutics, Inc. payments to acquire investments for the quarter ending 2023-03-31 was $17.53M, a 357.36% increase year-over-year.
- Zevra Therapeutics, Inc. payments to acquire investments for the quarter ending 2022-12-31 was $29.00K, a 99.81% decline year-over-year.
- Zevra Therapeutics, Inc. payments to acquire investments for the quarter ending 2022-09-30 was $0.00.
- Zevra Therapeutics, Inc. payments to acquire investments for fiscal 2023 was $45.81M, a 92.00% increase from fiscal 2022.
- Zevra Therapeutics, Inc. payments to acquire investments for fiscal 2022 was $23.86M, a 54.72% increase from fiscal 2021.
- Zevra Therapeutics, Inc. payments to acquire investments for fiscal 2021 was $15.42M.
- Zevra Therapeutics, Inc. payments to acquire investments for fiscal 2020 was $0.00.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month | Payments to Acquire Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | $129.00K 10-Q · filed 2024-08-14 | ||||
| 2023-12-31 | $45.81M 10-K · filed 2024-04-01 | ||||
| 2023-06-30 | -$59.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $17.47M 10-Q · filed 2024-08-14 | $17.50M derived: sum of 3 quarters · filed 2024-08-14 | $17.50M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $17.53M 10-Q · filed 2023-05-15 | $17.55M derived: sum of 2 quarters · filed 2024-04-01 | $17.55M derived: sum of 3 quarters · filed 2024-04-01 | $37.55M derived: sum of 4 quarters · filed 2024-04-01 | |
| 2022-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $29.00K derived: sum of 2 quarters · filed 2024-04-01 | $20.03M derived: sum of 3 quarters · filed 2024-04-01 | $23.86M 10-K · filed 2024-04-01 | $22.54M 10-K · filed 2023-03-07 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $20.00M derived: sum of 2 quarters · filed 2023-08-14 | $23.83M 10-Q · filed 2022-11-10 | $39.25M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $23.83M 10-Q · filed 2023-08-14 | $39.25M derived: sum of 3 quarters · filed 2023-08-14 | $39.25M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $3.83M 10-Q · filed 2023-05-15 | $19.25M derived: sum of 2 quarters · filed 2023-05-15 | $19.25M derived: sum of 3 quarters · filed 2023-05-15 | $19.25M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $15.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $15.42M derived: sum of 2 quarters · filed 2023-03-07 | $15.42M derived: sum of 3 quarters · filed 2023-03-07 | $15.42M 10-K · filed 2023-03-07 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $0.00 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | $0.00 10-K · filed 2022-03-31 | ||||
| 2017-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $6.46M derived: sum of 2 quarters · filed 2019-03-01 | $15.71M derived: sum of 3 quarters · filed 2019-03-01 | $27.38M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $423.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $9.68M derived: sum of 2 quarters · filed 2018-11-09 | $21.34M 10-Q · filed 2018-11-09 | $36.35M derived: sum of 4 quarters · filed 2018-11-09 | |
| 2017-06-30 | $9.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $20.92M 10-Q · filed 2018-08-10 | $35.93M derived: sum of 3 quarters · filed 2018-08-10 | $45.14M derived: sum of 4 quarters · filed 2018-08-10 | |
| 2017-03-31 | $11.67M 10-Q · filed 2018-05-11 | $26.68M derived: sum of 2 quarters · filed 2018-05-11 | $35.89M derived: sum of 3 quarters · filed 2018-05-11 | $86.85M derived: sum of 4 quarters · filed 2018-05-11 | |
| 2016-12-31 | $15.01M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $24.22M derived: sum of 2 quarters · filed 2018-03-30 | $75.18M derived: sum of 3 quarters · filed 2018-03-30 | $89.85M 10-K · filed 2018-03-30 | |
| 2016-09-30 | $9.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $60.17M derived: sum of 2 quarters · filed 2017-11-09 | $74.84M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $50.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $65.63M 10-Q · filed 2017-08-10 | |||
| 2016-03-31 | $14.67M 10-Q · filed 2017-05-22 | ||||
| 2015-12-31 | $19.00M 10-K · filed 2018-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |